

AbbVie Pipeline Update

April 2026



abbvie

AbbVie R&D Pipeline

Phase 1

- ABBV-243 (β 7) Autoimmune Diseases
- ABBV-319 (CD19 ADC) SLE, Sjorgren's Disease
- ABBV-547 (IL-23) Autoimmune Diseases
- ABBV-619 (CD19 CAR-T) Autoimmune Diseases
- ABBV-701 (TL1A) IBD
- ABBV-722 (LPAR1i) SSc & IPF
- ABBV-722 (LPAR1i) + Rinvoq (JAK1i) Autoimmune Diseases
- ABBV-848 (IRAK4i) RA
- ABBV-324 (GPC3 ADC) HCC / SQ-NSCLC
- ABBV-514 (CCR8) Solid Tumors
- ABBV-711 (PARP7i) Solid Tumors
- ABBV-901 (FR α ADC) Ovarian Cancer
- ABBV-969 (PSMA/STEAP1 ADC) mCRPC
- Alveltamig* (DLL3/DLL3/CD3) SCLC
- ABBV-1480 (RC148)* (PD-1/VEGF) Solid Tumors
- KST-6051 (KRASi)* Solid Tumors
- Temab-A (c-Met ADC) Solid Tumors
- ABBV-438 (CD38 ADC) R/R MM
- ABBV-2001* (CD38/BCMA/CD3) R/R MM
- Etentamig (BCMA/CD3) MM Combinations
- SIM0500* (GPRC5D/BCMA/CD3) R/R MM
- Surzetoclax (ABBV-453) (BCL2i) R/R MM
- UB-VV111* (CD19 CAR-T) LBCL, CLL
- ABBV-1042 (M4 Agonist) Bipolar Mania
- ABBV-1758 (3pE-A β) Alzheimer's Disease
- Emraclidine (M4 PAM) Psychosis
- ABBV-6628 (C5) Geographic Atrophy
- ABBV-295 (Amylin) Obesity

Phase 2

- ABBV-142 (LPAR1) IPF
- ABBV-382 (α 4 β 7) + Skyrizi (IL-23) CD
- ABBV-8736 (TREM1) CD
- Lutikizumab (IL-1 α /1 β) + Ravagalimab (CD40) RA
- Lutikizumab (IL-1 α /1 β) + Skyrizi (IL-23) PsA
- ABBV-706 (SEZ6 ADC) 1L SCLC
- Elahere (FR α ADC) PSOC (420)
- Elahere (FR α ADC) Ovarian Cancer (FLORENZA)
- IMGN-151 (FR α ADC) Gynecologic Cancers
- Livmoniplimab (GARP+TGF β 1) NSCLC
- Temab-A (c-Met ADC) CRC
- Temab-A (c-Met ADC) GEA
- Temab-A (c-Met ADC) Met-Amplified Solid Tumors
- Temab-A (c-Met ADC) NSCLC
- Epkinly* (CD20/CD3) B-Cell NHL
- Epkinly* (CD20/CD3) R/R CLL and Richter's Syndrome
- Etentamig (BCMA/CD3) AL Amyloidosis
- Pivekimab Sunirine (CD123 ADC) AML
- ABBV-932* (D2/D3 Agonist) Bipolar Depression
- ABBV-932* (D2/D3 Agonist) GAD
- ABBV-1354 (KOR Antagonist) Bipolar Depression
- ABBV-1354 (KOR Antagonist) MDD
- ABBV-2002 (PAR-2) Migraine Prevention
- Bretisilocin (5-HT2AR Agonist) MDD
- Emraclidine (M4 PAM) Schizophrenia
- GemibotA Ventral Hernia Repair
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma

Registrational / Phase 3

- Lutikizumab (IL-1 α /1 β) HS
- Rinvoq (JAK1i) HS
- Rinvoq (JAK1i) SLE
- ABBV-706 (SEZ6 ADC) R/R SCLC
- Elahere (FR α ADC) + Bevacizumab PSOC (GLORIOSA)
- Temab-A (c-Met ADC) + Bevacizumab 3L+ CRC
- Epkinly* (CD20/CD3) + R-CHOP 1L DLBCL
- Epkinly* (CD20/CD3) + Lenalidomide R/R DLBCL
- Epkinly* (CD20/CD3) + Rituximab/Lenalidomide 1L FL
- Etentamig (BCMA/CD3) 3L+ MM
- Qulipta (CGRP) Menstrual Migraine Prevention
- Ubrevely (CGRP) Menstrual Migraine Prevention
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Armour Thyroid (T3T4) Hypothyroidism

Submitted

- Rinvoq (JAK1i) Alopecia Areata
- Rinvoq (JAK1i) Vitiligo
- Pivekimab Sunirine (CD123 ADC) BPDCN
- Qulipta (CGRP) Migraine Acute Treatment (INTL)
- Tavapadon (D1/D5 Partial Agonist) Parkinson's Disease
- TrenibotE Glabellar Lines
- Reproxalap (RASP)* Dry Eye Disease

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

As of April 29, 2026

Excludes devices in development

*AbbVie Partnered assets

AbbVie - Anticipated Key Pipeline Events

	2026	2027
Regulatory Approvals	<p>Rinvoq Vitiligo Skyrizi Crohn's Disease Subcutaneous Induction Epkinly + Rituximab/Lenalidomide 2L FL (INTL) Pivekimab Sunirine BPDCN Qulipta Migraine Acute Treatment (INTL) Tavapadon Parkinson's Disease TrenibotE Glabellar Lines</p>	<p>Rinvoq Alopecia Areata Epkinly + R-CHOP 1L DLBCL Epkinly + Lenalidomide 2L DLBCL Transplant Ineligible Etentamig Monotherapy 3L MM Qulipta Menstrual Migraine Prevention (EU) Ubrelvy Menstrual Migraine Prevention (US)</p>
Regulatory Submissions	<p>Rinvoq Vitiligo Rinvoq Alopecia Areata Skyrizi Crohn's Disease Subcutaneous Induction Epkinly + R-CHOP 1L DLBCL Epkinly + Lenalidomide 2L DLBCL Transplant Ineligible Etentamig Monotherapy 3L MM Qulipta Menstrual Migraine Prevention (EU)</p>	<p>Lutikizumab Hidradenitis Suppurativa Rinvoq Hidradenitis Suppurativa Rinvoq Systemic Lupus Erythematosus Elahere + Bevacizumab 2L PSOC Maintenance Ubrelvy Menstrual Migraine Prevention (US) ABBV-RGX-314 wAMD Subretinal Delivery</p>
Ph3/Registrational Data Readouts	<p>Lutikizumab Ph3 Hidradenitis Suppurativa Rinvoq Ph3 Hidradenitis Suppurativa Skyrizi Ph3 Crohn's Disease Subcutaneous Induction Epkinly + R-CHOP Ph3 1L DLBCL Epkinly + Lenalidomide Ph3 2L DLBCL Transplant Ineligible Etentamig Monotherapy Ph3 3L MM Qulipta Ph3 Menstrual Migraine Prevention Ubrelvy Ph3 Menstrual Migraine Prevention</p>	<p>Rinvoq Ph3 Systemic Lupus Erythematosus Elahere + Bevacizumab Ph3 2L PSOC Maintenance Temab-A + Bevacizumab Ph3 3L+ CRC ABBV-RGX-314 Ph3 wAMD Subretinal Delivery</p>
Early-Stage Data Readouts	<p>ABBV-382 + Skyrizi Ph2 CD Lutikizumab + Skyrizi Ph2 CD Lutikizumab + Ravagalimab Ph2 RA ABBV-969 Ph1 mCRPC ABBV-2001 Ph1 MM Etentamig Ph1 2L MM Combinations IMGN-151 Ph2 PROC Livmoniplimab Ph2 1L NSCLC Temab-A Ph2 comboTx 2L CRC ABBV-932 Ph2 Bipolar Depression Bretisilocin Ph2 MDD Emraclidine Ph2 Schizophrenia Emraclidine Ph1 Psychosis ABBV-295 Ph1 Obesity</p>	<p>ABBV-319 Ph1 SLE/Sjorgren's Disease ABBV-619 Ph1 RA/SLE Lutikizumab + Skyrizi Ph2 PsA ABBV-514 Ph1 Solid Tumors Etentamig Ph1 1L MM Combinations Surzetoclast Ph1 MM Temab-A Ph2 comboTx 1L CRC Temab-A Ph2 comboTx 1L GEA Temab-A Ph2 comboTx 1L NSCLC Temab-A Ph2 comboTx 1L PDAC Temab-A Ph2 monoTx 2L NSCLC EGFR-mutant ABBV-932 Ph2 Generalized Anxiety Disorder ABBV-1354 Ph2 MDD ABBV-2002 Ph2 Migraine Prevention ABBV-RGX-314 Ph2 wAMD Suprachoroidal Delivery</p>

As of April 29, 2026

AbbVie's Partnered Assets

- ABBV-932 developed in partnership with Gedeon Richter.
- ABBV-1480 (RC148) developed in partnership with RemeGen.
- ABBV-2001 developed in partnership with Ichnos Glenmark Innovation (IGI).
- ABBV-RGX-314 co-developed by REGENXBIO and AbbVie.
- Alveltamig developed by Suzhou Zelgen Biopharmaceuticals. AbbVie holds an exclusive option to develop and commercialize Alveltamig.
- KST-6051 developed by Kestrel Therapeutics. AbbVie holds an exclusive option to acquire Kestrel.
- Epkinly developed in partnership with Genmab.
- Reproxalap currently developed by Aldeyra. AbbVie holds an exclusive option to license, co-develop, and co-commercialize reproxalap.
- SIM0500 developed by Simcere Zaiming. AbbVie holds an exclusive option to develop and commercialize SIM0500.
- UB-VV111 developed by Umoja Biopharma. AbbVie holds an exclusive option to develop and commercialize UB-VV111.